bioAffinity Files S-1 as Lung Cancer Test Sales Triple
bioAffinity Technologies filed an S-1 as its noninvasive CyPath Lung cancer test, which shows 92% sensitivity in clinical trials, posted nearly 300% year-over-year unit sales growth in April 2026.
